

**FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10**

8V731063035US  
Express Mail Label Number

May 3, 2006  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

LIAU ET AL.

APPLICATION NO: 10/537,847

FILED: JUNE 8, 2005

FOR: ENDOTHELIAL CELL SPECIFICALLY BINDING PEPTIDES

**MS: PCT**


Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**SUBMISSION OF SEQUENCE LISTING**  
**INCLUDING STATEMENT OF VERIFICATION**

In response to the Notification of Defective Response of April 3, 2006, Applicants submit this corrected Sequence Listing. While the sequences have not been changed, the description of the features (<220>) has been supplemented to indicate that the artificial sequences were derived from human and animal adenovirus peptide sequences. It is believed that this amendment complies with the defects indicated in the Notification.

In accordance with 37 CFR 1.821(f) and 1.825(a), it is hereby certified that the appended computer readable form of the Sequence Listing (1.821(e)) is identical to the paper copy of the Sequence Listing that is part of the specification (1.821(c)).

Respectfully submitted,

  
John T. Prince  
Attorney for Applicants  
Reg. No. 43,019

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(617) 871-3346  
Date: May 3, 2006